Quantcast
Last updated on April 23, 2014 at 17:32 EDT

Latest Swedish Orphan Biovitrum Stories

2014-04-14 12:32:51

Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These...

2013-08-08 08:29:40

LYNBROOK, N.Y., Aug. 8, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(® )in the U.S. and XIAPEX(®)( )in the EU, today reported its financial results for the second quarter ended June 30, 2013 and provided a corporate update. "We continue to make steady progress in the clinical development and commercial growth of XIAFLEX. We are anticipating a major landmark related...

2013-07-16 20:21:37

LYNBROOK, N.Y., July 16, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has entered into a collaboration with Swedish Orphan Biovitrum AB (Sobi) for the long-term development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of...

2013-07-16 00:20:42

-Sobi Obtains Exclusive Rights for One Commercial and One Development Indication for XIAPEX- CHESTERBROOK, Pa., and STOCKHOLM, July 16, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (STO: SOBI) announced today that they have entered into a long-term collaboration for the development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the treatment of...

2013-02-26 08:29:37

BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2012 financial results will be released prior to the market open on Tuesday, March 19, 2013. Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on March 19, 2013, to discuss these results and to answer questions. To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151...

2012-11-06 08:28:13

SOUTH PLAINFIELD, N.J., Nov. 6, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty pharmaceutical company developing therapies for patients with rare disorders and significant medical needs. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "We are...

2012-10-29 03:21:05

STOCKHOLM, October 29, 2012 /PRNewswire/ -- Dr. Heather Cook Appointed Director of Regulatory Affairs and Marek Poszepczynski as Director of Business Development Pharmalink AB, a Swedish specialty pharma company, today announces it has appointed Dr. Heather Cook as Director of Regulatory Affairs and Mr. Marek Poszepczynski as Director of Business Development. Dr. Cook brings to Pharmalink over 15 years of experience within the...

2010-10-26 07:30:00

WOODCLIFF LAKE, N.J., Oct. 26 /PRNewswire/ -- Strativa Pharmaceuticals today announced that it has entered into an amended and restated license and supply agreement with Swedish Orphan Biovitrum (Sobi) covering the European development and commercialization rights of Strativa's Nascobal (cyanocobalamin) Vitamin B12 Nasal Spray. Strativa acquired the worldwide rights to Nascobal from QOL Medical, LLC in March 2009, which included a pre-existing agreement with Sobi. Under the terms of...